研報掘金丨國盛證券:潤澤科技第二成長曲線加速發力,首予“買入”評級
國盛證券研報指出,潤澤科技(300442.SZ)是園區級數據中心龍頭,採用批發模式與下遊電信運營商及終端互聯網及CSP 客戶深度合作。AIDC業務快速擴展,營收佔比超傳統IDC業務,後續訂單充足,第二成長曲線加速發力。認爲公司憑藉出色的園區設計管理能力和下遊客戶渠道,有望持續維持較高的盈利能力,在同類型企業中率先享受AIDC 行業紅利。AI應用進入爆發階段,推理端算力需求大幅增加,數據中心作爲AI基礎設施底座需求有望大幅增加,同時IDC向AIDC轉型加速。公司有望憑藉高上架率、領先行業的機櫃數及穩定的客戶率先受益,獲得新的營收增長動力。首次覆蓋給予“買入”評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.